On Oct. 14, the FDA announced a plan called the “Rare Disease Framework Initiative,” described in a new white paper, to build a “fit-for-purpose” approach to reviewing drugs and biologics for rare diseases. The FDA says the initiative aims to give developers of rare disease treatments clearer, more consistent guidance on the evidence needed for approval.
The FDA has built up its rare disease programs piece by piece over the last several years, but questions have persisted about whether it applies them evenly. A November 2024 Government Accountability Office (GAO) report identified 18 rare disease programs at the agency, most launched since 2019, and four of the seven drug sponsors GAO interviewed raised concerns about how the FDA applied its regulatory flexibilities. The new white paper cites the GAO report, says the number of programs has grown since, and says “the pace of progress has not matched the scale of the need.”
The FDA plans to review existing rare disease policies, procedures, programs, guidance and regulations, and says it “may consider revisions to existing regulations or, where appropriate, new regulatory provisions.” The paper does not specify which regulations it would change.
The paper sets goals including clearer evidence expectations, earlier patient input, greater use of outside disease experts and risk-based manufacturing review. It identifies shared resources, reviewer training and coordination across the FDA’s drug and biologics centers as ways to support more consistent reviews.
The paper says the framework “continues to adhere fully to the statutory requirements of safety and effectiveness,” but sets no eligibility criteria, evidence tiers or timeline.
Leerink Partners analyst Joseph Schwartz, in a note to clients reported by Healthcare Dive, wrote that the FDA “is not lowering the bar for rare disease, but it may be making the path to approval less of a guessing game.”
The FDA has framed it the same way. In a press release, Amy Comstock Rick, director of the FDA’s Rare Disease Innovation Hub, which leads the initiative, said the new framework “will enhance consistency and predictability for both sponsors and for patients.”
Two narrow policies, now a broad one
This is the agency’s third rare disease evidence policy since September 2025, joining the Rare Disease Evidence Principles and the plausible mechanism framework, both of which apply to narrow, tightly defined slices of rare diseases.
The Rare Disease Evidence Principles (RDEP), announced Sept. 3, 2025, apply to therapies that correct a known genetic defect in diseases affecting “generally less than 1,000 persons in the United States,” that cause progressive deterioration and that have no adequate alternative treatment.
The plausible mechanism framework, laid out in draft guidance issued in February 2026, targets an even narrower category: individualized therapies, such as gene editing and antisense oligonucleotides, for specific genetic conditions with a known biological cause. The guidance remains a non-binding draft.
The new framework is broader than either, covering rare diseases generally. It also raises the possibility of changing regulations, while RDEP and the plausible mechanism framework rest on guidance and review practice.
What’s next
The FDA will hold a public meeting Oct. 28, from 1 to 5 p.m. ET, at its White Oak campus and online. In a Federal Register notice published Oct. 16, the agency asked for comments on four areas: fit-for-purpose review based on attainable evidence, disease state and population; consistency and predictability; engagement with patients and outside experts; and chemistry, manufacturing and controls. It also invited comments on the roles of its drug and biologics centers in rare disease review. Comments are due Dec. 11 under docket FDA-2026-N-12214. The agency also plans sector-specific roundtables and internal feedback sessions to inform the framework’s development.
Filed Under: Regulatory affairs
